NKG2D- and T-cell receptor-dependent lysis of malignant glioma cell lines by human γδ T cells: Modulation by temozolomide and A disintegrin and metalloproteases 10 and 17 inhibitors

A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection

(2015) W. Deng et al.   SCIENCE

Effect of NKG2D ligand expression on host immune responses

(2015) Marine Champsaur et al.   IMMUNOLOGICAL REVIEWS

Novel Bispecific Antibodies Increase    T-Cell Cytotoxicity against Pancreatic Cancer Cells

(2014) H.-H. Oberg et al.   CANCER RESEARCH

Regulation of Ligands for the NKG2D Activating Receptor

(2013) David H. Raulet et al.   Annual Review of Immunology

Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: Heterogeneous involvement of the “a disintegrin and metalloproteases” 10 and 17

(2013) Guranda Chitadze et al.   INTERNATIONAL JOURNAL OF CANCER

Modulation of NKG2D ligand expression and metastasis in tumors by spironolactone via RXRγ activation

(2013) Wai-Hang Leung et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Butyrophilin 3A1 Plays an Essential Role in Prenyl Pyrophosphate Stimulation of Human V 2V 2 T Cells

(2013) H. Wang et al.   JOURNAL OF IMMUNOLOGY

Butyrophilin 3A1 binds phosphorylated antigens and stimulates human γδ T cells

(2013) Stefano Vavassori et al.   NATURE IMMUNOLOGY

A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells

(2013) Fabian Wolpert et al.   NEURO-ONCOLOGY

ADAM17, shedding, TACE as therapeutic targets

(2013) Stefan Rose-John   PHARMACOLOGICAL RESEARCH

Engineered Drug Resistant γδ T Cells Kill Glioblastoma Cell Lines during a Chemotherapy Challenge: A Strategy for Combining Chemo- and Immunotherapy

(2013) Lawrence S. Lamb et al.   PLoS One

Generation of Soluble NKG2D Ligands: Proteolytic Cleavage, Exosome Secretion and Functional Implications

(2013) G. Chitadze et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

New prospects on the NKG2D/NKG2DL system for oncology

(2013) Evelyn Ullrich et al.   OncoImmunology

Adoptive Cell Therapies for Glioblastoma

(2013) Kevin Bielamowicz et al.   Frontiers in Oncology

Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human    T-cell subset

(2012) C. Harly et al.   BLOOD

Exosome removal as a therapeutic adjuvant in cancer

(2012) Annette M Marleau et al.   Journal of Translational Medicine

Current concepts and management of glioblastoma

(2011) Matthias Preusser et al.   ANNALS OF NEUROLOGY

Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours

(2011) A J Nicol et al.   BRITISH JOURNAL OF CANCER

Palmitoylation of MICA, a ligand for NKG2D, mediates its recruitment to membrane microdomains and promotes its shedding

(2011) Sonia Agüera-González et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

The human NKG2D ligand ULBP2 can be expressed at the cell surface with or without a GPI anchor and both forms can activate NK cells

(2011) L. Fernandez-Messina et al.   JOURNAL OF CELL SCIENCE

Modulation of NKG2D-ligand Cell Surface Expression Enhances Immune Cell Therapy of Cancer

(2011) Baocheng Huang et al.   JOURNAL OF IMMUNOTHERAPY

TGF-  downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients

(2011) C. A. Crane et al.   NEURO-ONCOLOGY

Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme

(2011) C. E. Fadul et al.   NEURO-ONCOLOGY

Thermal- and Oxidative Stress Causes Enhanced Release of NKG2D Ligand-Bearing Immunosuppressive Exosomes in Leukemia/Lymphoma T and B Cells

(2011) Malin Hedlund et al.   PLoS One

Temozolomide: Mechanisms of Action, Repair and Resistance

(2011) Jihong Zhang et al.   Current Molecular Pharmacology

Natural Killer Cell Cytotoxicity Is Suppressed by Exposure to the Human NKG2D Ligand MICA*008 That Is Shed by Tumor Cells in Exosomes

(2010) O. Ashiru et al.   CANCER RESEARCH

ADAM-17: the enzyme that does it all

(2010) Monika Gooz   CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY

Differential Mechanisms of Shedding of the Glycosylphosphatidylinositol (GPI)-anchored NKG2D Ligands

(2010) Lola Fernández-Messina et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

NKG2A inhibits NKG2C effector functions of γδ T cells: implications in health and disease

(2010) Daniela F. Angelini et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Preclinical evaluation of ex vivo expanded/activated γδ T cells for immunotherapy of glioblastoma multiforme

(2010) Nichole L. Bryant et al.   JOURNAL OF NEURO-ONCOLOGY

Synergistic therapeutic effects of cytokine-induced killer cells and temozolomide against glioblastoma

(2010) Nam   ONCOLOGY REPORTS

Toll-like Receptors 3 and 7 Agonists Enhance Tumor Cell Lysis by Human    T Cells

(2009) H. Shojaei et al.   CANCER RESEARCH

Role of ADAMs in Cancer Formation and Progression

(2009) M. J. Duffy et al.   CLINICAL CANCER RESEARCH

DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vγ9Vδ2 T cells

(2009) Olivier Toutirais et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Clinical and immunological evaluation of zoledronate-activated Vγ9γδ T-cell-based immunotherapy for patients with multiple myeloma

(2009) Yu Abe et al.   EXPERIMENTAL HEMATOLOGY

An integrated view of the regulation of NKG2D ligands

(2009) Noam Stern-Ginossar et al.   IMMUNOLOGY

Brief Residence at the Plasma Membrane of the MHC Class I-Related Chain B Is Due to Clathrin-Mediated Cholesterol-Dependent Endocytosis and Shedding

(2009) S. Aguera-Gonzalez et al.   JOURNAL OF IMMUNOLOGY

Characterization and immunotherapeutic potential of γδ T-cells in patients with glioblastoma

(2009) Nichole L. Bryant et al.   NEURO-ONCOLOGY

Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma

(2008) Jaafar Bennouna et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Synergistic Inhibition with a Dual Epidermal Growth Factor Receptor/HER-2/neu Tyrosine Kinase Inhibitor and a Disintegrin and Metalloprotease Inhibitor

(2008) L. Witters et al.   CANCER RESEARCH

Tumor-Associated MICA Is Shed by ADAM Proteases

(2008) I. Waldhauer et al.   CANCER RESEARCH

Soluble NKG2D ligands: prevalence, release, and functional impact

(2008) Helmut Rainer Salih   Frontiers in Bioscience-Landmark

NKG2D ligands in tumor immunity

(2008) N Nausch et al.   ONCOGENE